Continuous subcutaneous insulin infusion methods with a hyaluronan degrading enzyme

摘要

Disclosed is the use of a composition comprising a hyaluronidase and a composition comprising an insulin for manufacture of a medicament for treatment of diabetes in combination with continuous subcutaneous insulin infusion (CSII) to minimize changes in insulin absorption that occur during a course of CSII therapy, wherein: -the composition comprising the insulin is formulated for continuous subcutaneous insulin infusion (CSII) therapy to be administered for more than one day; -the composition comprising the hyaluronidase is formulated to be administered as a single dose bolus injection for administration separately from the insulin in the CSII therapy prior to infusion of the insulin composition by CSII; and -the composition comprising the hyaluronidase is formulated for direct administration in an amount that minimizes changes in insulin absorption that occurs over a course of continuous subcutaneous insulin infusion (CSII).